Kinarus Therapeutics Holding AG Logo

Kinarus Therapeutics Holding AG

ISIN: CH0009115129 | Ticker: KNRS | LEI: 506700VDL70GGMHR5758
Sector: Health Care – Sub-Industry: Pharmaceuticals
Country: Switzerland
Website Investor Relations

About Kinarus Therapeutics Holding AG

Company Description

Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.

Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.

Recently, in response to the global challenge of COVID-19, Kinarus has initiated clinical evaluation of its combination therapy to treat patients suffering from SARS-CoV-2 infection. Kinarus has discovered that KIN001 has anti-viral activity against SARS-CoV-2, including against its variants of concern. KIN001 also possesses anti-inflammatory and anti-fibrotic activity.

Year founded

2017

Served area

Worldwide

Headquarters

Hochbergerstrasse 60C, 4057 Basel – Switzerland

Filings & Publications

2021
2022

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2022

Report
Q1
H1
Q3
FY
Consolidated Report
Corporate Governance Report
Company Presentation
ENG
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
31.10.23 None Executive member Sell CHF 4,248.75
07.09.23 None Executive member Sell CHF 11,713.02
23.06.23 None Executive member Sell CHF 45,028.85
13.06.23 None Executive member Sell CHF 38,761.94
05.06.23 None Executive member Sell CHF 1,417,143.65
02.06.22 None Executive member Buy CHF 7,441,035.53
02.06.22 None Non-Executive member Buy CHF 2,483,942.78
02.06.22 None Executive member Buy CHF 922,192.69
02.06.22 None Executive member Buy CHF 399,716.30
02.06.22 None Non-Executive member Buy CHF 337,068.73

Capital markets information

ISIN

CH0009115129

LEI

506700VDL70GGMHR5758

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

SIX Swiss Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.